Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Share-based Compensation: 2013-2024

Historic Share-based Compensation for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to $21.0 million.

  • Seres Therapeutics' Share-based Compensation fell 52.11% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 48.83%. This contributed to the annual value of $21.0 million for FY2024, which is 38.50% down from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Share-based Compensation is $21.0 million, which was down 38.50% from $34.1 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Share-based Compensation registered a high of $34.1 million during FY2023, and its lowest value of $8.8 million during FY2020.
  • Over the past 3 years, Seres Therapeutics' median Share-based Compensation value was $25.5 million (recorded in 2022), while the average stood at $26.9 million.
  • Per our database at Business Quant, Seres Therapeutics' Share-based Compensation spiked by 129.17% in 2021 and then crashed by 38.50% in 2024.
  • Seres Therapeutics' Share-based Compensation (Yearly) stood at $8.8 million in 2020, then spiked by 129.17% to $20.2 million in 2021, then rose by 26.01% to $25.5 million in 2022, then skyrocketed by 33.82% to $34.1 million in 2023, then plummeted by 38.50% to $21.0 million in 2024.